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Abstract
Background: Non-coding RNA molecules, such as microRNAs, may play an important role in
carcinogenesis. Recent studies have indicated that microRNAs are involved in initiation and
progression of various malignancies. However, little work has been done to compare the
microRNA expression patterns in oral cancer. In this study, we constructed an animal model of
oral squamous cell carcinoma to investigate expression profiles of microRNAs in oral
carcinogenesis.
Methods:  The animal model of oral squamous cell carcinoma was conducted by tri-weekly
(Monday, Wednesday, and Friday) painting with 5% DMBA in acetone. Six Syrian hamsters,
including three from the treated group and three from the control group, were used as a training
group for microRNA microarray analysis. All microarray data were analyzed by Significance
Analysis of Microarrays (SAM) and CLUSTER 3.0 software, and this result was further confirmed
by qRT-PCR assay.
Results: Seventeen microRNAs were differentially expressed in oral squamous cell carcinoma.
Five microRNAs (hsa-miR-21, hsa-miR-200b, hsa-miR-221, hsa-miR-338, and mmu-miR-762) were
significantly upregulated and twelve microRNAs (hsa-miR-16, hsa-miR-26a, hsa-miR-29a, hsa-miR-
124a, hsa-miR-125b, mmu-miR-126-5p, hsa-miR-143, hsa-miR-145, hsa-miR-148b, hsa-miR-155,
hsa-miR-199a, and hsa-miR-203) were down-regulated in cancer tissues. The expression levels of
hsa-miR-21 and hsa-miR-16 seen with Stem-loop qRT-PCR were also seen in microarray analysis
in all samples.
Conclusion:  Our findings identified specific microRNA expression in oral squamous cell
carcinoma and suggested that microRNAs have a role in oral carcinogenesis.
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Background
MicroRNAs (miRNAs) are small, noncoding RNAs (~20–
22 nucleotides) that have critical functions in various bio-
logical processes [1]. These naturally occurring miRNAs
function by binding to target mRNAs, resulting in the deg-
radation or translational inhibition of the mRNA, based
upon the degree of complementarity with it. First
described in 1993 in the nematode Caenorhabditis elegans
[2], to date, thousands of miRNAs have been cloned in
higher eukaryotes and a number have been shown to play
a role in cell proliferation, apoptosis, growth and mor-
phogenesis [3-5]. At present, dysregulation of miRNAs has
been shown to be involved in tumor initiation and pro-
gression.
The explosion of data on miRNAs and cancer has put
them in the spotlight over the past few years. Numerous
studies have highlighted the suspected role of miRNAs in
tumorigenesis and have established that profiling of these
miRNAs represents an informative method for determin-
ing developmental lineage and the differentiation state of
various malignancies. The initial connection of miRNAs
and cancer was elucidated in leukemia and hematological
malignancies, later spurring interest in solid malignan-
cies. For example, one of the first lines of evidence for
direct involvement of miRNAs in cancer was the finding
that miR-15 and miR-16 are located within a 30 kb dele-
tion in chronic lymphocytic leukemia (CLL), and that
both genes were deleted or underexpressed in most cases
of this cancer [6]. Abnormal expression of microRNAs has
been found in a variety of solid tumors, including colon,
breast, lung, thyroid, glioblastomas, prostate, lympho-
mas, ovarian, hepatocellular, cervical, and pancreatic car-
cinomas [7-17].
Comparatively, oral cancer has received very little atten-
tion in this area of genome profiling. It is identified as a
significant public health threat worldwide because its
treatment often produces dysfunction and distortions in
speech, mastication and swallowing, dental health, and
even in the ability to interact socially. It is one of the 10
most frequent cancers in human males worldwide, with
about two thirds of all cases occurring in developing
countries [18]. The most common type of oral cancer is
squamous cell carcinoma. At present, the management of
oral squamous cell carcinoma (OSCC) includes combina-
tions of surgery, radiotherapy, and chemotherapy [19].
Despite improvements in these therapies, the 5-year sur-
vival rate has not improved significantly and remains at
about 50% [20]. In clinical practice, treatment planning
and prognosis for patients with OSCC are mainly based
on the TNM classification. TNM classification provides
significant diagnostic information concerning the tumor,
but does not give the clinician sufficient therapeutic bio-
logical information, such as the metastatic potential or the
sensitivity or resistance of the tumor to radiotherapy and
chemotherapy [21]. There is an urgent need for diagnostic
methods for distinguishing high-risk patients from other
patients in order that optimal managements can be
applied.
As such, some of the urgent priorities in this field are the
need to identify and elucidate novel genes or pathways
that may choreograph this disease. In the present study,
by using the miRNA microarray technique, we have meas-
ured the relative expression of microRNAs in 7,12-dime-
thyl-benz- [a]-anthrance (DMBA)-induced OSCC in
Syrian hamster. We hope that it can contribute to early
diagnosis and treatment of this malignancy.
Methods
Animals
The construction of the animal model was conducted at
West China College of Stomatology, Sichuan University.
Twenty-four adult male (150 to 250 g) Syrian hamsters (6
weeks old; sydw, Sichuan, China) were randomly divided
into two experimental groups (Group A and B) and one
control group (Group C) (n = 8 for each group). After one
week of acclimatization, both cheek pouches of each ani-
mal in the experimental groups were treated with 5%
DMBA (Sigma, St Louis, MO, USA) in acetone. DMBA was
applied tri-weekly (Monday, Wednesday and Friday) with
a paintbrush. The animals from group A received carcino-
gen for about 12 weeks. Group B received carcinogen
about 12 weeks, with an additional 6-week period of
observation. Group C received no treatment and served as
blank control. The animal groupings and protocol of car-
cinogen application are summarized in Table 1.
All tissue samples were collected under pentobarbital
anesthesia for histopathological examination and miRNA
microarray. Six Syrian hamsters, including three from
group A and B (12 wk, 18 wk, and 18 wk, respectively)
and three from group C (blank control group), were used
as a training group for miRNA microarray analysis. All of
the handling measures used with the Syrian hamsters were
in accordance with approved guidelines (Guidelines for
the Care and Use of Laboratory Animals) established by
the Chinese Council on Animal Care.
Fabrication of the miRNA microarray
The miRNA microarrays were obtained from CapitalBio
Corporation (Beijing, China), corresponding to the cur-
rent release of the Sanger miRNA database (http://micro
rna.sanger.ac.uk; August 2007). The individual oligonu-
cleotide probe was printed in triplicate on chemically
modified glass slides in a 21 × 21 spot configuration of
each subarray. The spot diameter was 130 mm, and dis-
tance from center to center was 185 mm. A total of 924
mature miRNA sequences were assembled and integratedJournal of Experimental & Clinical Cancer Research 2009, 28:64 http://www.jeccr.com/content/28/1/64
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into our miRNA microarray design. These microarray
probes included 677 human miRNAs (including 122 pre-
dicted miRNA sequences) [22], 292 rat, and 461 mouse
mature miRNAs from the miRNA Registry. All of the oli-
gonucleotide probes were presented in triplicate in one
microarray, and each of the four subarrays contained 16
controls (Zip5, Zip13, Zip15, Zip21, Zip23, Zip25, Y2, Y3,
U6, New-U2-R, tRNA-R, hsa-let-7a, hsa-let-7b, hsa-let-7c,
50%DMSO (Dimethyl Sulfoxide), and Hex). The limited
sequence length of miRNAs left little consideration for
probe design strategy, so all miRNA probe sequences were
designed to be complementary to the full-length mature
miRNA.
Nucleic acid extraction, labeling, and hybridization
Total RNA from each tissue sample was extracted with Tri-
zol reagent (Invitrogen, Carlsbad, USA), and the low-
molecular-weight RNA was isolated by a PEG solution
precipitation method, according to a previous protocol
[23]. We adopted the T4 RNA ligase labeling method
according to Thomson' protocol; that is, 4 μg of low-
molecular-weight RNA was labeled with 500 ng of 5'-
phosphate-cytidyl-uridyl-cy3-3' (Dharmacon, Chicago,
USA) with 2 units of T4 RNA ligase (NEB, Beijing, China)
[24]. The hybridization chamber was laid on a three-
phase tiling agitator BioMixerTM II (CapitalBio, Beijing,
China) to promote microfluidic circulation under the cov-
erslip. The hybridization was performed in a water bath at
42°C overnight. The array was then washed with two con-
secutive washing solutions (0.2% SDS, 2 × SSC at 42°C
for 5 min, and 0.2% SSC for 5 min at room temperature).
This procedure was repeated twice for each sample.
Microarray imaging and data analysis
The miRNA microarray from CapitalBio Corporation was
a single-channel fluorescence chip; all oligonucleotide
probes were labeled with Cy3 fluorescent dye (green). Flu-
orescence scanning used a double-channel laser scanner
(LuxScan 10 K/A, CapitalBio). The figure signal was trans-
formed to a digital signal using image analysis software
(LuxScan3.0, CapitalBio). Signal intensities for each spot
were calculated by subtracting local background from
total intensities. Raw data were normalized and analyzed
using the Significance Analysis of Microarrays (SAM, ver-
sion 2.1, Stanford University, CA, USA) software [25]. The
raw data was Log2 transformed and median centered by
arrays and genes using the adjust data function of CLUS-
TER 3.0 software for cluster analysis [26].
Stem-loop qRT-PCR for miRNAs
All miRNA-specific primers were designed according to
miRNA sequences. The universally expressed U6 was used
as an internal control. Reverse transcriptase reactions con-
tained 2.5 ng/μL purified total RNA, 50 nM stem-loop
reverse transcription (RT) primer, 1 × RT buffer, 0.25 mM
of each of dNTPs, 3.33 U/ml MultiScribe reverse tran-
scriptase, 0.25 U/ml RNase inhibitor. The 7.5 μL reactions
were incubated in an MJ Research PTC-225 Thermocycler
for 30 min at 16°C, 30 min at 42°C, 5 min at 85°C, and
then held at 4°C. All reverse transcriptase reactions were
run in duplicate. Stem-loop qRT-PCR was performed as
described in published references [27]. The 10 μl PCR
reaction contained 0.67 μl RT product, 1 × PCR Master
Mix, 1.5 μM forward primer, and 0.7 μM reverse primer.
The reactions were incubated at 95°C for 10 min, fol-
lowed by 40 cycles of 95°C for 15 s and 60°C for 1 min.
All reactions were run in triplicate. Melting curves were
performed using Dissociation Curves software (Funglyn)
to ensure only a single product was amplified, and the
specificity of samples was confirmed by running on a 3%
agarose gel. All reagents from MBI Company (MBI Fer-
mentas, Maryland, USA) were used following the manu-
facturer's protocols.
Results
The effect of DMBA-induced oral carcinogenesis
Two animals died during the experimental period (one
each from Groups A and B). Histologically, all samples
from Group C appeared normal, with a thin epithelium
devoid of rete ridges (Figure 1A~C). Five animals from
Group A and seven animals from Group B developed SCC
(Figure 1D~F). The tumor diameters ranged from 1.5 mm
to 15 mm in both groups, with an average diameter of 5 ±
1.69 mm and 8.7 ± 2.55 mm for Group A and B, respec-
Table 1: Protocol and effect of DMBA-induced oral carcinogenesis on cheek pouch of syrian hamster
Group Animals Treatment protocol Histological type Mean diameter of tumors
NM PP CIS SCC (mm)
Experiment Group
A 7 5%DMBA-12 week-killed 0 1 1 5 5 ± 1.69
B 7 5%DMBA-18 week-killed 0 0 0 7 8.7 ± 2.55
Control Group
C 8 No treatment-18 week-killed 8 0 0 0 -
5%DMBA:7,12-dimethyl benz [a]anthrance in acetone;
NM:normal;PP:papilloma;CIS:carcinoma in situ;SCC:squamous cell carcinomaJournal of Experimental & Clinical Cancer Research 2009, 28:64 http://www.jeccr.com/content/28/1/64
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DMBA-induced oral carcinogenesis in the hamster cheek pouch (H&E staining) Figure 1
DMBA-induced oral carcinogenesis in the hamster cheek pouch (H&E staining). (A~C) Normal epithelium; (D) 
SCC; (E) Papillary SCC; (F) SCC.Journal of Experimental & Clinical Cancer Research 2009, 28:64 http://www.jeccr.com/content/28/1/64
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tively (Table 1). Most of the squamous cell carcinomas
were classified as well-differentiated or moderately differ-
entiated.
miRNA microarray analysis
RNA gel electrophoresis demonstrated that the quality of
the RNA was good. SAM was performed to identify differ-
ences in miRNA expression between cancerous and nor-
mal samples. SAM calculated a score for each gene on the
basis of the change in expression relative to the S.D. of all
measurements. The SAM data indicated that 5 miRNA
genes were significantly overexpressed and that 12 miRNA
genes were significantly underexpressed in cancer sam-
ples, with fold changes>2. These results are shown in
Table 2. For increased confidence, we repeated each
microarray assay twice. The scatter diagrams and correla-
tion assessment of all spots showed that the reproducibil-
ity and reliability were good (Figure 2). The supervised
cluster analysis, based on differentially expressed miR-
NAs, generated a tree with clear distinction between can-
cerous and normal tissues (Figure 3).
Stem-loop qRT-PCR for miRNAs
Our miRNA microarray detection platform was con-
structed by CapitalBio, and several previous comparative
studies between microarray platforms and analysis proce-
dures had indicated the very high sensitivity, reproducibil-
ity, and specificity using their recommended methods
[28]. To confirm the microarray findings, we determined
the hsa-miR-21 and hsa-miR-16 expression levels by
Stem-loop qRT-PCR in all samples. The miRNAs were
found to have the same expression levels as seen by micro-
array analysis (Figure 4).
Discussion
Since Sally first established the DMBA-induced oral car-
cinogenesis model in the cheek pouch of Syrian hamster
in 1954, it has become a classic animal model of OSCC
[29]. In this study, we successfully constructed this animal
model of OSCC using tri-weekly applications of a 5%
solution of DMBA in acetone onto the cheek pouch of Syr-
ian hamsters over about a 12-week period.
For models like the hamster model for OSCC, microarray
assay provides a powerful tool for analyzing both miRNA
expression patterns and quantitative expression levels, as
it profiles thousands of genes simultaneously. This tech-
nology is much more efficient than the now outmoded
and time-consuming methods used in earlier work, and is
becoming the broadest miRNA research tool available
[30]. We used a newly designed microarray platform spe-
cific for the analysis of the expression of some 924 mam-










squamous cell carcinoma vs normal cheek pouch tissue
hsa-miR-21 2.590 up 2.495 1.371 Up-regulated in glioblastomas[11], breast[8], colon[7], lung[9], pancreatic[17], 
thyroid[10], and ovarian cancer[15]
hsa-miR-200b 2.192 up 1.645 0.964 Up-regulated in ovarian cancer[15]
hsa-miR-221 2.018 up 1.561 0.988 Up-regulated in CLL[8], glioblastomas[11], thyroid[10], and pancreatic 
cancer[17]
hsa-miR-338 2.436 up 1.323 0.493
mmu-miR-762 2.379 up 1.863 1.052
hsa-miR-16 0.182 down -2.501 0.458 Down-regulated in CLL[8], and prostate cancer[12]
hsa-miR-26a 0.135 down -2.288 1.148 Down-regulated in prostate[12], and ovarian cancer[15]
hsa-miR-29a 0.245 down -1.532 0.785 Down-regulated in ovarian cancer[15]
hsa-miR-124a 0.216 down -1.819 0.702 Down-regulated in colon[7], breast[8] and lung cancer[9]
hsa-miR-125b 0.414 down -1.282 0.418 Down-regulated in breast[8], lung[9], ovarian[15], cervical[16], and prostate 
cancer[12]
mmu-miR-126-5p 0.424 down -1.117 0.536
hsa-miR-143 0.393 down -1.245 0.605 Down-regulated in prostate[12], Lung[9], breast[8], hepatocellular[14], 
colon[7], cervical[16], and ovarian cancer[15]
hsa-miR-145 0.317 down -2.130 0.899 Down-regulated in prostate[12], Lung[9], breast[8], hepatocellular[14], 
ovarian[15], cervical[16], and colon cancer[7]
hsa-miR-148b 0.317 down -2.130 0.899 Down-regulated in pancreatic[17], and colon cancer[7]
hsa-miR-155 0.376 down -1.374 0.486 Up-regulated in CLL[8], thyroid[10], lymphomas[13], lung[9], breast cancer[8] 
Down-regulated in pancreatic cancer[17]
hsa-miR-199a 0.261 down -1.411 0.847 Down-regulated in prostate[12], and hepatocellular cancer[14]
hsa-miR-203 0.175 down -1.925 0.910 Down-regulated in colon[7], and breast cancer[8] Up-regulated in ovarian 
cancer[15]
CLL: chronic lymphocytic leukemiaJournal of Experimental & Clinical Cancer Research 2009, 28:64 http://www.jeccr.com/content/28/1/64
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malian miRNAs. The platform and assay are similar in
many respects to other spotted oligonucleotide microar-
ray designs, but have several important differences in
application [24]. First, a modified spotting buffer and an
advanced hybridization system were used in this study.
These measures have both previously shown to result in
large improvements in the local signal intensity and glo-
bal signal uniformity, as well as in the elimination of the
doughnut spots commonly seen on spotted oligonucle-
otide arrays. These improvements are believed to be due
to better blocking of the slide surface chemistry [31]. A
detailed assessment of the quality control and reproduci-
bility of this new miRNA microarray platform has been
published [32]. Using miRNA microarray analysis, we
evaluated miRNA expression profiles of OSCC and nor-
mal cheek mucosa tissues, and identified seventeen miR-
NAs that were up-regulated and down-regulated in cancer
tissues compared with normal tissues. In addition, hsa-
miR-338, mmu-miR-762, and mmu-miR-126-5p were
not apparently altered in any of the tumors.
Recently, there have been several studies regarding
miRNA expression profiles of various tumor types and the
general finding was that overall microRNA expression
could differentiate normal versus cancerous tissues [7-17].
Among these previous studies, some miRNAs expression
levels were similar to those found in the present study.
These results are summarized in Table 2. Lu et al. has dem-
onstrated the use of microRNA signatures as an important
advance in cancer diagnosis. Their work indicated that
microRNA-based identification of cancers was superior in
terms of correctly diagnosing cancer of unknown prima-
ries when compared to mRNA classification [33].
Hundreds of miRNAs have been identified in recent years
and miRNA functional identification has become one of
Experimental variation and reproducibility assessment from twelve microarray hybridizations in six different samples Figure 2
Experimental variation and reproducibility assessment from twelve microarray hybridizations in six different 
samples. Scatter diagram showing high reproducibility between the replicate experiments of every sample. The R-value in 
each microarray analysis showing that most of the average correlations are well above 0.9, indicating high reproducibility. Panel 
A~C: self-hybridization results obtained after probing the microarray with the same RNA sample prepared from three normal 
tissues and labeled separately with Cy3 dye. Panel D~F: self-hybridization results obtained after probing the microarray with 
the same RNA sample prepared from three cancer tissues and labeled separately with Cy3 dye.
 Journal of Experimental & Clinical Cancer Research 2009, 28:64 http://www.jeccr.com/content/28/1/64
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the most active research fields in biology. However, only
a limited number of miRNAs has yet been defined func-
tionally through overexpression, misexpression, and in
vitro knockdown [34]. Recently, several studies have indi-
cated that increased or decreased miRNA levels play a crit-
ical role in head and neck carcinogenesis. Using miRNA
microarray analysis, Chang et al. identified seven miRNAs
that were up-regulated (mir-21, let-7, 18, 29c, 142-3p,
155, and 146b) and one miRNA that was down-regulated
(mir-494) in HNSCC primary tissue and cell lines. More-
over, they demonstrated that cytochrome c release was
decreased by mir-21 knockdown, which suggested mir-21
inhibited several mRNAs that then led to a cascade of
events that prevented apoptosis and increased cellular
proliferation [35]. In addition, Tran et al. identified 54
commonly expressed miRNA genes, which included 31
up-regulated and 23 down-regulated miRNAs. The profil-
ing data represented nine cell lines from four different
anatomical head and neck sites [36]. In comparison to
these previous studies, the expression tendency of four
miRNAs (hsa-miR-21, hsa-miR-155, hsa-miR-200b, and
hsa-miR-221) were found to be similar in our study. The
similarity in expression of hsa-miR-21 in previous and our
studies in head and neck squamous cell carcinoma and
cancer cell lines is of particular interest. These findings, in
conjunction with our study, demonstrate that miR-21
may play a critical role in head and neck carcinogenesis.
This miRNA should therefore become a focus for the
Supervised hierarchical clustering analysis of miRNA expression Figure 3
Supervised hierarchical clustering analysis of miRNA expression. 17 miRNAs expression profile (from SAM result) of 
6 samples were clustered using Cluster 3.0. 6 samples were successfully separated into 2 discrete groups.Journal of Experimental & Clinical Cancer Research 2009, 28:64 http://www.jeccr.com/content/28/1/64
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development of anti-microRNA preclinical therapeutic
strategies for OSCC abrogation in the future.
Considering only the highly conserved microRNAs that
were common in both humans and hamsters, we used the
TargetScan program to check if the SAM-retrieved microR-
NAs were conservative types. In addition to mmu-miR-
762 and mmu-miR-126-5p, fifteen other microRNAs were
found highly conserved in most vertebrates. At present,
mmu-miR-762 and mmu-miR-126-5p are not known to
have been reported in any tumors.
Since miRNAs can function as oncogenes or as tumor sup-
pressor genes, they provide a logical therapeutic target for
cancer treatment [37]. Modified anti-miRNA oligonucle-
otides (AMOs) have been used by many groups to inhibit
miRNAs with oncogenic properties. For example, Chan et
al. successfully applied 2'-O-methyl- and DNA/LNA-
mixed oligonucleotides to specifically knockdown miR-
21, in order to investigate the potential contribution of
this miRNA in the regulation of apoptosis-associated
genes in glioblastoma cell lines [38]. Thus, to supplement
and/or enhance the function of tumor suppressor miR-
NAs due to a deletion or a loss of function mutation, a
therapeutic approach could entail exogenous delivery of
corrective synthetic miRNAs in the form of double-
stranded miRNA mimics [39]. Takamizawa et al. found
that enforced expression of let-7 in the lung adenocarci-
noma cell line A549 inhibited lung cancer cell growth in
vitro. This holds promise that let-7 may be useful in treat-
ment of lung cancer or in enhancing currently available
treatments [40]. The microRNA field is rapidly develop-
ing, and the functions and signaling pathways of increas-
ingly greater numbers of miRNAs are being carefully
studied. The activation or silencing of miRNAs identified
in the present study and in previous studies could prove
pivotal in the design of therapeutic strategies for OSCC
qRT-PCR analysis of miR-21 and miR-16 in three cancer and three normal tissues Figure 4
qRT-PCR analysis of miR-21 and miR-16 in three cancer and three normal tissues. A: The expression level of miR-
21 in all samples. B: The expression level of miR-16 in all samples. C: The electrophoresis result of PCR products. U 6 expres-
sion was used as a loading control.Journal of Experimental & Clinical Cancer Research 2009, 28:64 http://www.jeccr.com/content/28/1/64
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treatment in the future, although we are presently far from
that point.
Conclusion
In summary, the specific miRNA expression levels identi-
fied by our study were similar with those reported in other
studies, and suggested that a number of miRNAs could be
significant in OSCC development. The next step will be to
perform functional research of the three microRNAs (hsa-
miR-338, mmu-miR-762, and mmu-miR-126-5p) that
were not found to have been altered in any malignancies.
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